Argos Therapeutics Obtains $42,500,000 New Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=559f5392-6ca0-432b-b536-3c69488fa984 - Date
8/26/2013 - Company Name
Argos Therapeutics - Mailing Address
4233 Technology Drive Durham, NC 27704 USA - Company Description
Argos Therapeutics (NASDAQ: ARGS) is developing breakthrough immunotherapies that target the unique features of a patient´s disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company´s “Arcelis” technology, trains the immune system to recognize and attack the disease. - Website
http://www.argostherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$42,500,000 - Transaction Round
Undisclosed - Proceeds Purposes
The money will be used to fund a Phase 3 study – the final phase required by regulators before seeking approval to put a drug on the market – that was launched in January and ultimately is expected to include 450 patients. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
